GCA And Risk Of Cancer Or Visual Loss - Dr. Olga Petryna Save
Dr. Olga Petryna from EULAR2020 Virtual Conference
OP0149 Tocilizumab Treats Visual Loss in GCA
OP0143 GCA in Israel and risk of Cancer
Transcription
Good evening. This is Olga Petrina presenting from the virtual EULAR twenty twenty Congress. Today I would like to talk about giant cell arteritis. Abstract OP-one 149 is an interesting observational study which is a monocentric study from Switzerland evaluating one hundred and ninety two patients with giant cell arthritis treated with Totelizumab. In the beginning of the observation baseline thirty seven percent of patients experienced visual impairment and about seven point eight percent of patients had visual loss.
It was found that patients who experienced visual changes were usually older, had lower CRP levels. They showed no signs of aortic involvement on an MRI and also those patients were treated on average for thirteen point eight months with tocilizumab. At the end of observation it was found that only one patient who was treated with tocilizumab experienced visual loss and when it comes to patients with visual impairment thirty two percent of patients were able to achieve improvement of their visual changes and very small percentage of patients less than seven percent continue to experience visual impairment. This suggests that thecilizumab may have a preventative effect on visual loss and also could be beneficial for patients with visual impairment in GCA. Second poster I would like to talk about is OP-one 143 which is a national database study from Israel evaluating patients with GCA from 2002 and until the end of the study in 2018 and the purpose of the study was to evaluate for risk of cancer in patients with giant cell arteritis.
In this study it was found that unfortunately patients with giant cell arteritis are at the higher risk of cancer overall with hazard ratio of one point two nine. The most common types of cancer in giant cell arthritis patients were sarcoma with hazard ratio 2.14. That was the highest one followed by kidney cancer at hazard ratio 1.6. Hematological malignancies were common with leukemia, non Hodgkin's lymphoma and Hodgkin's lymphoma being the highest on the list. And it was also found that patients with giant cell arteritis had shorter duration of symptoms before cancer diagnosis with the time from GCA to cancer diagnosis forty eight months on average as opposed to fifty eight months in control group.
I hope you find this interesting and if you would like to find out more, please follow us on RheumNow. Thank you and have a good rest of your day.
It was found that patients who experienced visual changes were usually older, had lower CRP levels. They showed no signs of aortic involvement on an MRI and also those patients were treated on average for thirteen point eight months with tocilizumab. At the end of observation it was found that only one patient who was treated with tocilizumab experienced visual loss and when it comes to patients with visual impairment thirty two percent of patients were able to achieve improvement of their visual changes and very small percentage of patients less than seven percent continue to experience visual impairment. This suggests that thecilizumab may have a preventative effect on visual loss and also could be beneficial for patients with visual impairment in GCA. Second poster I would like to talk about is OP-one 143 which is a national database study from Israel evaluating patients with GCA from 2002 and until the end of the study in 2018 and the purpose of the study was to evaluate for risk of cancer in patients with giant cell arteritis.
In this study it was found that unfortunately patients with giant cell arteritis are at the higher risk of cancer overall with hazard ratio of one point two nine. The most common types of cancer in giant cell arthritis patients were sarcoma with hazard ratio 2.14. That was the highest one followed by kidney cancer at hazard ratio 1.6. Hematological malignancies were common with leukemia, non Hodgkin's lymphoma and Hodgkin's lymphoma being the highest on the list. And it was also found that patients with giant cell arteritis had shorter duration of symptoms before cancer diagnosis with the time from GCA to cancer diagnosis forty eight months on average as opposed to fifty eight months in control group.
I hope you find this interesting and if you would like to find out more, please follow us on RheumNow. Thank you and have a good rest of your day.
If you are a health practitioner, you may Login/Register to comment.
Due to the nature of these comment forums, only health practitioners are allowed to comment at this time.